CD70-CD27 轴在癌症免疫治疗中:预测性生物标志物和治疗靶点
The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target.
CD27-CD70相互作用被认为是T细胞启动和扩增的阳性共刺激途径。
69.6分
★★★☆☆
ALL SOURCES
The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target.
CD27-CD70相互作用被认为是T细胞启动和扩增的阳性共刺激途径。
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
对于因上皮-间质转化(EMT)介导而对 EGFR 酪氨酸激酶抑制剂(TKIs)产生获得性耐药的 EGFR 突变非小细胞肺癌(NSCLC)患者,需要有效的治疗策略。
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.
尽管最近出现了免疫检查点抑制剂,转移性NSCLC患者的临床结局仍然很差,这凸显了开发新型疗法以增强NSCLC抗肿瘤免疫反应的未满足需求。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。